

Reducing variation in the treatment of men with high-risk/locally advanced prostate cancer

A National Prostate Cancer Audit quality improvement workshop

Thursday 16th December 2021, 09.00–11.00

Chair: Noel Clarke, NPCA Uro-Oncological Clinical Lead	
09.00 – 09.10	Welcome and introduction to the day: Stephen Fry
	Impact of the Covid-19 pandemic
09.10 – 09.25	Findings from the NPCA: Julie Nossiter, NPCA Audit Lead
09.25 – 09.35	Update on NHS England's <i>Data and Action Plan</i> : Peter Johnson, National Clinical Director for Cancer, NHS England
09.35– 09.55	Panel discussion: Lessons learnt during the pandemic and implications for the recovery of prostate cancer services Noel Clarke (Chair) Amit Bahl, Clinical Oncologist, Bristol Haematology and Oncology Centre, University Hospitals Bristol Gokul Kandaswamy, Consultant Urological Surgeon, Swansea Bay University Health Board & NPCA Clinical Lead, Wales Ben Challacombe, Consultant Urological Surgeon, Guy's and St Thomas' Pauline Bagnall, Uro-oncology Nurse Specialist, Northumbria Healthcare NHS Foundation Trust
Chair: Heather Payne, NPCA Oncological Clinical Lead	
	Determinants of variation in the under-treatment and types of treatment of men with high risk/locally advanced disease
09.55 – 10.10	Findings from the NPCA: Matt Parry, NPCA Clinical Fellow
10.10 – 10.20	Optimising the management of patients with high risk/locally advanced disease – improving the outcomes of older men: Danielle Harari, Geriatric-oncology Consultant and Clinical Lead, Geriatric Oncology liaison Development Team, Guy's and St. Thomas'
10.20 – 10.30	How do we reduce variation in access to treatment for all men? The experience of black and ethnic minority groups: Jonathan Makanjuola, Consultant Urological Surgeon, King's College Hospital
10.30 – 10.55	Q&A session: discussion & action plan Heather Payne (Chair) Danielle Harari Jonathan Makanjuola Members of the NPCA PPI Forum
10.55 – 11.00	Patient view & reflections: Steve Allen, Tackle Prostate Cancer